{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:44:56Z","timestamp":1785800696897,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the long-term risk factors for post-operative vitreous hemorrhage (VH) within 24 months following vitrectomy for proliferative diabetic retinopathy (PDR), evaluate the protective efficacy of preoperative anti-VEGF therapy, and quantify the associated secondary surgical burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 735 eyes from 735 PDR patients. A 24-month survival analysis was employed to categorize patients into VH (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009179) and non-VH (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009556) groups. Independent predictors were identified using univariate and multivariate Cox proportional hazards models. A sensitivity analysis was performed on a \u201cpure hemorrhage model\u201d (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009676) by excluding eyes with post-operative tractional retinal detachment (TRD) to isolate the direct vascular-stabilizing effect of anti-VEGF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall cumulative incidence of post-operative VH was 18.4% at 12 months and 25.7% at 24 months. Multivariate Cox analysis revealed that preoperative anti-VEGF injection emerged as the strongest protective factor, associated with a 63% reduction in VH hazard (HR 0.37; 95% CI, 0.27\u20130.51;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). This protective effect remained robust in the sensitivity analysis (HR 0.32;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), which is consistent with a potential vascular-stabilizing effect independent of anatomical success. Independent risk factors included severe fibrovascular traction (HR 1.93;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003), younger age, higher HbA1c, and elevated serum creatinine (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Patients in the VH group had significantly poorer final visual outcomes (1.33\u2009\u00b1\u20090.75 vs. 0.92\u2009\u00b1\u20090.60 LogMAR;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and a markedly higher reoperation rate (31.3% vs. 7.2%). Notably, hemorrhage-related indications accounted for 58.4% of the total secondary surgical workload.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Post-operative VH is a dominant driver of long-term visual impairment and secondary surgical burden in PDR. Preoperative anti-VEGF supports the hypothesis that preoperative anti-VEGF may contribute to sustained microvascular stabilization. Vitreous hemorrhage-related indications accounted for 58.4% of secondary surgical interventions, suggesting that clinical strategies aimed at reducing recurrent VH could meaningfully decrease the overall reoperation burden in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00871-w","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:34:59Z","timestamp":1780072499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative anti-VEGF and the cumulative risk of post-operative vitreous hemorrhage in PDR: a 2-year survival analysis and evaluation of surgical burden"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuxian","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"11","key":"871_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021;128(11):1580\u201391.","journal-title":"Ophthalmology"},{"issue":"3","key":"871_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364.","journal-title":"Diabetes Care"},{"issue":"1","key":"871_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/aos.14482","volume":"99","author":"V Schreur","year":"2021","unstructured":"Schreur V, Brouwers J, Van Huet RAC, Smeets S, Phan M, Hoyng CB, de Jong EK, Klevering BJ. Long-term outcomes of vitrectomy for proliferative diabetic retinopathy. Acta Ophthalmol. 2021;99(1):83\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"871_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/ICU.0000000000000946","volume":"34","author":"S Pandit","year":"2023","unstructured":"Pandit S, Ho AC, Yonekawa Y. Recent advances in the management of proliferative diabetic retinopathy. Curr Opin Ophthalmol. 2023;34(3):232\u20136.","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"871_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12886-020-01532-8","volume":"20","author":"Y Ding","year":"2020","unstructured":"Ding Y, Yao B, Hang H, Ye H. Multiple factors in the prediction of risk of recurrent vitreous haemorrhage after sutureless vitrectomy for non-clearing vitreous haemorrhage in patients with diabetic retinopathy. BMC Ophthalmol. 2020;20(1):292.","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"871_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41433-022-02167-3","volume":"37","author":"SZ Tan","year":"2023","unstructured":"Tan SZ, Steel DH, Stanzel BV, Bedersdorfer M, Szurman P, Saidkasimova S, Schielke KC, Kumaran N, Laidlaw DAH. Safety and effectiveness of pre-emptive diabetic vitrectomy in patients with severe, non-fibrotic retinal neovascularisation despite panretinal photocoagulation. Eye (Lond). 2023;37(8):1553\u20137.","journal-title":"Eye (Lond)"},{"issue":"7","key":"871_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/IAE.0b013e3181a8eb88","volume":"29","author":"WR Lo","year":"2009","unstructured":"Lo WR, Kim SJ, Aaberg TM, Sr., Bergstrom C, Srivastava SK, Yan J, Martin DF, Hubbard GB. 3rd: Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina. 2009;29(7):926\u201331.","journal-title":"Retina"},{"issue":"12","key":"871_CR8","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0161-6420(84)34099-4","volume":"91","author":"MA Novak","year":"1984","unstructured":"Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984;91(12):1485\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"871_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/0974-9233.106387","volume":"20","author":"T Sato","year":"2013","unstructured":"Sato T, Morita S, Bando H, Sato S, Ikeda T, Emi K. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20(1):51\u20135.","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"8","key":"871_CR10","first-page":"Cd008214","volume":"2015","author":"JM Smith","year":"2015","unstructured":"Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2015;2015(8):Cd008214.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"871_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10792-025-03722-z","volume":"45","author":"J Mei","year":"2025","unstructured":"Mei J, Zhou H, Deng C, Wang S, Guo B, Lin W, Lin Z, Lin K, Wu R, Lin Z. Long-term outcomes of vitrectomy for proliferative diabetic retinopathy: a real world study in China. Int Ophthalmol. 2025;45(1):366.","journal-title":"Int Ophthalmol"},{"key":"871_CR12","doi-asserted-by":"crossref","unstructured":"Zhan J, Sun G, Li H, Deng X, Huang X, Wu Q, Liu B, Lu L, Zhao X. Timing of pre-operative anti-VEGF for vitrectomy in proliferative diabetic retinopathy: a competing-risks analysis of a large cohort. Ophthalmol Retina. 2025.","DOI":"10.1016\/j.oret.2025.12.019"},{"key":"871_CR13","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.2147\/OPTH.S516425","volume":"19","author":"G Li","year":"2025","unstructured":"Li G, Zhang M, Ke Y, Zheng C, Tan L, Li Y, Pazo EE, Chen C, Ren X. Efficacy of Intravitreal Conbercept in Vitrectomy for Proliferative Diabetic Retinopathy: An Integrated Meta-Analysis and Bibliometric Study. Clin Ophthalmol. 2025;19:3465\u201386.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"871_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12886-023-02940-2","volume":"23","author":"M Zhao","year":"2023","unstructured":"Zhao M, Chandra A, Xu J, Li J. Factors related to postoperative vitreous hemorrhage after small-gauge vitrectomy in proliferative diabetic retinopathy patients. BMC Ophthalmol. 2023;23(1):215.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"871_CR15","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1111\/aos.14292","volume":"98","author":"K Takayama","year":"2020","unstructured":"Takayama K, Someya H, Yokoyama H, Kimura T, Takamura Y, Morioka M, Sameshima S, Ueda T, Ogata N, Kitano S, et al. Prognostic factors of revitrectomy for complications in eyes with proliferative diabetic retinopathy: a retrospective multicentre study. Acta Ophthalmol. 2020;98(4):e434\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"871_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000098253","volume":"221","author":"P Kroll","year":"2007","unstructured":"Kroll P, Rodrigues EB, Hoerle S. Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica. 2007;221(2):78\u201394.","journal-title":"Ophthalmologica"},{"key":"871_CR17","doi-asserted-by":"crossref","unstructured":"Bahr TA, Bakri SJ. Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy. Life (Basel). 2023;13(5).","DOI":"10.3390\/life13051098"},{"issue":"7","key":"871_CR18","doi-asserted-by":"publisher","first-page":"e2675","DOI":"10.1371\/journal.pone.0002675","volume":"3","author":"EJ Kuiper","year":"2008","unstructured":"Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I, Van Noorden CJ, Goldschmeding R, Schlingemann RO. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE. 2008;3(7):e2675.","journal-title":"PLoS ONE"},{"issue":"5","key":"871_CR19","first-page":"Cd008214","volume":"5","author":"P Dervenis","year":"2023","unstructured":"Dervenis P, Dervenis N, Smith JM, Steel DH. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2023;5(5):Cd008214.","journal-title":"Cochrane Database Syst Rev"},{"key":"871_CR20","doi-asserted-by":"publisher","first-page":"1067670","DOI":"10.3389\/fpubh.2022.1067670","volume":"10","author":"J Qu","year":"2022","unstructured":"Qu J, Chen X, Liu Q, Wang F, Li M, Zhou Q, Yao J, Li X. Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial. Front Public Health. 2022;10:1067670.","journal-title":"Front Public Health"},{"issue":"2","key":"871_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/IIO.0000000000000027","volume":"54","author":"J El Annan","year":"2014","unstructured":"El Annan J, Carvounis PE. Current management of vitreous hemorrhage due to proliferative diabetic retinopathy. Int Ophthalmol Clin. 2014;54(2):141\u201353.","journal-title":"Int Ophthalmol Clin"},{"key":"871_CR22","doi-asserted-by":"crossref","unstructured":"Semeraro F, Cancarini A, dell\u2019Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:582060.","DOI":"10.1155\/2015\/582060"},{"issue":"3","key":"871_CR23","doi-asserted-by":"publisher","first-page":"e36963","DOI":"10.1097\/MD.0000000000036963","volume":"103","author":"U Yilmaz","year":"2024","unstructured":"Yilmaz U, Ak\u00e7ao\u011flu T, Avunduk MA, Kaya H, Par\u00e7a O. Investigation of the recurrent vitreous hemorrhage risk factors after early 25G vitrectomy in diabetic vitreous hemorrhage. Med (Baltim). 2024;103(3):e36963.","journal-title":"Med (Baltim)"},{"issue":"1","key":"871_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40942-025-00758-2","volume":"11","author":"G Li","year":"2025","unstructured":"Li G, Wu R, Zhang X, Zheng M, Chen Q. Combined phacoemulsification and vitrectomy for proliferative diabetic retinopathy: an increased risk of early recurrence but not long-term neovascular glaucoma. Int J Retina Vitreous. 2025;11(1):130.","journal-title":"Int J Retina Vitreous"},{"key":"871_CR25","doi-asserted-by":"crossref","unstructured":"Kameda Y, Saeki T, Hanai K, Suzuki Y, Uchigata Y, Babazono T, Kitano S. Is chronic kidney disease affecting the postoperative complications of vitrectomy for proliferative diabetic retinopathy? J Clin Med. 2021;10(22).","DOI":"10.3390\/jcm10225309"},{"issue":"1","key":"871_CR26","doi-asserted-by":"publisher","first-page":"14858","DOI":"10.1038\/s41598-019-51411-6","volume":"9","author":"K Takayama","year":"2019","unstructured":"Takayama K, Someya H, Yokoyama H, Takamura Y, Morioka M, Sameshima S, Ueda T, Kitano S, Tashiro M, Sugimoto M, et al. Risk Factors of Neovascular Glaucoma After 25-gauge Vitrectomy for Proliferative Diabetic Retinopathy with Vitreous Hemorrhage: A Retrospective Multicenter Study. Sci Rep. 2019;9(1):14858.","journal-title":"Sci Rep"},{"key":"871_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/DMSO.S362074","volume":"15","author":"D Ke","year":"2022","unstructured":"Ke D, Hong Y, Jiang X, Sun X. Clinical Features and Vitreous Biomarkers of Early-Onset Type 2 Diabetes Mellitus Complicated with Proliferative Diabetic Retinopathy. Diabetes Metab Syndr Obes. 2022;15:1293\u2013303.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"871_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12886-019-1179-x","volume":"19","author":"X Hu","year":"2019","unstructured":"Hu X, Pan Q, Zheng J, Song Z, Zhang Z. Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab. BMC Ophthalmol. 2019;19(1):200.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"871_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00055735-200106000-00016","volume":"12","author":"S Sharma","year":"2001","unstructured":"Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol. 2001;12(3):230\u20134.","journal-title":"Curr Opin Ophthalmol"},{"key":"871_CR30","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2147\/DMSO.S429938","volume":"16","author":"H Guo","year":"2023","unstructured":"Guo H, Li W, Wang K, Nie Z, Zhang X, Bai S, Duan N, Li X, Hu B. Analysis of Risk Factors for Revitrectomy in Eyes with Diabetic Vitreous Hemorrhage. Diabetes Metab Syndr Obes. 2023;16:2865\u201374.","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00871-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:04:00Z","timestamp":1785798240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00871-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00871-w","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of the First Affiliated Hospital of Shantou University Medical College (Approval ID: B-2025-212). Due to the retrospective nature of the study, the requirement for informed consent was waived by the IRB.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"103"}}